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This data article contains the data related to the research article
‘Transient silencing of Npr3 gene expression improved the circu-
latory levels of atrial natriuretic peptides and attenuated β-
adrenoceptor activation-induced cardiac hypertrophic growth in
experimental rats’ (Venkatesan et al., 2016 [1]). The siRNA-Npr3
loaded chitosan nanoparticles were synthesized using ionotropic
gelation method, where the positive charge of the chitosan inter-
acts with the negative charge of STPP and siRNA-Npr3. The phy-
sicochemical properties of the synthesized siRNA-Npr3 loaded
chitosan nanoparticles were studied by dynamic light scattering,
FE-SEM and HR-TEM analysis. In addition, the loading efﬁciency
and stability of the nanoparticles were also studied. Further, the
gene silencing efﬁcacy, hemocompatibility and biocompatibility
were studied using Wistar rats (in vivo), isolated red blood cells
and H9c2 cardiomyoblast cells, respectively.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.ejphar.2016.04.037
nom.ac.in (E. Vellaichamy).
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ject areaNanotechnology, Molecular biology.ype of data Figure.
ow data was
acquiredFE-SEM, HR-TEM, DLS, Zeta potential, agarose gel electrophoresis, hemo-
compatibility assay, MTT assay, RT-PCR and Western blotting.ata format Raw and analyzed.
xperimental
factorsSynthesis of siRNA-Npr3 loaded chitosan nanoparticles by ionotropic
gelation.xperimental
featuresHypertrophied H9c2 cells and hypertrophied rats were treated with different
concentration of target 1 and 2 siRNA-Npr3 loaded chitosan nanoparticles to
validate its gene silencing efﬁcacy.ata source location NA.
ata accessibility Data are available within this article.D
Value of the data
 This data describes the synthesis and characterization of the siRNA-Npr3 loaded chitosan nano-
particles for in vitro and in vivo applications.
 This data validated the biocompatibility, hemocompatibility and gene silencing efﬁcacy of siRNA-
Npr3 loaded chitosan nanoparticles in in vitro and in vivo model system.
 This method of siRNA-Npr3 loaded chitosan nanoparticles can be utilized as a drug delivery vehicle
for in vitro and in vivo applications.1. Data
The data provided here displays the synthesis, characterization, biocompatibility and hemocompat-
ibility of siRNA-Npr3 loaded nanoparticles. Further, the gene silencing efﬁcacy of the synthesized siRNA-
Npr3 nanoparticles was demonstrated in the H9c2 cells in vitro and in rat hearts in vivo.2. Experimental design, materials and methods
2.1. Materials
Chitosan (75–85% of deacetylation, low molecular weight), Npr3 speciﬁc siRNA – Target 1: 50-
GUUUGCUAAUGGCCUUCUA[dT][dT]-30 and 50 UAGAAGGCCAUUAGCAAAC[dT][dT]-30 (CAT# SASI_Rn01_
00055729), Target 2: 50-GACUAUGCUUUCUUCAACA[dT][dT]-30 and 50-UGUUGAAGAAAGCAUAGUC[dT]
[dT]-30 (CAT# SASI_Rn02_00260355) and sodium tripolyphosphate were procured from Sigma-Aldrich,
USA. Dulbecco's Modiﬁed Eagle's Medium (DMEM), Trypsin-EDTA, fetal bovine serum (FBS) and antibiotic
antimycotic solution were purchased from HiMedia, India. cDNA conversion kit was procured from
Thermo scientiﬁc, USA. Red dye PCR master mix was purchased from Merck Millipore, German. Gene
speciﬁc primers were purchased from Euroﬁns Scientiﬁc, Luxembourg. Primary antibody for NPR-C and
HRP labeled secondary antibody were purchased from Santa Cruz biotechnology, USA.
2.2. Synthesis and characterization of siRNA-Npr3 loaded chitosan nanoparticles
The siRNA-Npr3 loaded chitosan nanoparticles were synthesized by mixing chitosan solution
(1 mg/ml chitosan in 0.2 M sodium acetate buffer, pH 4.5) to a mixture containing STPP solution
Fig. 1. Synthesis, characterization and stability of siRNA-Npr3 loaded chitosan nanoparticles: A) Dynamic light scattering
analysis, B) FE-SEM analysis; insert in B) HR-TEM analysis, C) Loading efﬁciency of the nanoparticles D) Representative gel
retardation assay of siRNA-Npr3 loaded chitosan nanoparticles where, Lane-1: 100 bp DNA ladder, Lane-2: nacked siRNA-Npr3
target 1, Lane-3: nacked siRNA-Npr3 target 2, Lane-4 and 5: chitosan nanoparticles, Lane-6: siRNA-Npr3 loaded chitosan
nanoparticles (target 1), Lane-7: siRNA-Npr3 loaded chitosan nanoparticles (target 2).
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siRNA-Npr3. The contents were mixed and vortexed for 1 min on a vortex mixer and kept undisturbed
for 30 min [2]. The synthesized nanoparticles were puriﬁed by centrifuging at 31,000g for 20 min.
Further, the nanoparticles were washed with ultrapure DNase/RNase free water and centrifugation
was repeated.
Fig. 1A shows the particle size analysis (DLS – Malvern Nano ZS, UK) of synthesized nanoparticles,
which revealed that the hydrodynamic size of the siRNA-Npr3 nanoparticles were in the range of
220717.5 nm. From the zeta potential analysis, the nanoparticles were found to possess a surface
charge of þ16.271.2 mV. It is evidenced from the FE-SEM – Fig. 1B (Hitachi SU6600, Germany) and
HR-TEM – insert in Fig. 1B (FEI TECNAI G2) analysis of the nanoparticles that the synthesized particles
were of fairly spherical in shape and evenly distributed.
2.3. Quantiﬁcation of siRNA-Npr3 loading efﬁciency
The loading efﬁciency of the siRNA-Npr3 in the siRNA-Npr3 loaded chitosan nanoparticles were
analyzed using UV–Vis spectrophotometer (Shimadzu UV 150-02, Japan) by comparing the A260 of the
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the naked siRNA-Npr3 [3]. The loading efﬁciency was calculated by using the following formula:
Loading efﬁciency¼A260 nm of siRNA present in the supernatant/A260 nm of total amount of siRNA
added for nanoparticles preparation*100 and the siRNA-Npr3 loading efﬁciency were observed to
100% (Fig. 1C).
2.4. Gel retardation assay
The stability and interaction strength between the chitosan and siRNA-Npr3 in the nanoparticles
was carried out by gel retardation assay. Brieﬂy, equal concentration of naked siRNA-Npr3, chitosan
nanoparticles and siRNA-Npr3 loaded chitosan nanoparticles were loaded on different wells of 4%
agarose gel for analyzing the stability of the nanoparticles [3]. The gel retardation assay showed that
the nanoparticles loaded with siRNA-Npr3 gets retarded in the well as evidenced by the retarded
movement of the nanoparticles, while the naked siRNA-Npr3 freely resolved in the agarose gel
(Fig. 1D).
2.5. Biocompatibility of siRNA-Npr3 loaded chitosan nanoparticles
To assess the biocompatibility of the nanoparticles, MTT assay was carried out on H9c2 cell line.
Brieﬂy, 5000 cells/well were seeded in 96 well plate and maintained in 10% FBS containing DMEM for
24 h. After 24 h, the cells were treated with either chitosan nanoparticles or siRNA-Npr3 loaded
chitosan nanoparticles or chitosan scrambled siRNA nanoparticles in serum free media for 48 h. Later,
the media was removed and 10 ml of MTT solution (5 mg/ml) was added to each well and incubated
for 4 h at dark. After the reaction, the MTT was removed and 100 ml of DMSO was added to all the
wells. The A570 was read by microplate reader [4]. Fig. 2A shows the results of the biocompatibility
assay, where none of the nanoparticles (chitosan, siRNA-Npr3 loaded chitosan nanoparticles, and
chitosan scrambled nanoparticles) tested exhibits cytotoxicity against H9c2 cells.
2.6. Hemolytic activity
The hemolytic activity of the nanoparticles was tested on isolated rat erythrocytes [5]. Brieﬂy, the
whole blood was processed and erythrocytes were collected in a vial. 5% v/v erythrocytes in PBS were
distributed to each tube and the volume of the tube was made up to 1 ml with nanoparticles samples
(chitosan nanoparticles or siRNA-Npr3 loaded chitosan nanoparticles or chitosan scrambled siRNA
nanoparticles) and PBS. Erythrocytes treated with 1% triton X 100 served as the positive control and
erythrocytes in PBS served as negative control. The reaction mixture was incubated for 1 h at 37 °C in
shaking condition. Then the tubes were centrifuged at 190g and the absorbance of the supernatant
was measured at 540 nm. The percentage of hemolysis¼[(A540 nm in siRNA-Npr3 loaded chitosan
nanoparticles supernatant solution – A540 nm in PBS)/(A540 in 1% Triton X-100 – A540 in PBS)]100.
Fig. 2B, shows the results of the hemolytic activity assay. The nanoparticles (150 mg/ml) were tested
individually on rat erythrocytes and found to be exhibit least toxicity as per ASTM standard which can
be considered as compatible [6].
2.7. Validation the gene silencing efﬁcacy of siRNA-Npr3 loaded chitosan nanoparticles
The in vivo gene silencing efﬁcacy and effective dosage ﬁxation of siRNA-Npr3loaded chitosan
nanoparticles were performed by intramyocardial injection of the nanoparticles. Brieﬂy, 2.5 or 5 mg of
siRNA-Npr3 containing nanoparticles/kg body weight was administered to the hypertrophied Wistar
rats. At the end of the experiment, the heart tissue was harvested and processed as described earlier
[1]. Fig. 2C and D shows the Western blotting and densitometric analysis of NPR-C protein expression
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expression was observed in the isoproterenol treated rat hearts, and treatment with 2.5 or 5 mg of
siRNA-Npr3 decreased the expression of NPR-C by 45% and 70% respectively.
To validate the gene silencing efﬁcacy of the siRNA-Npr3 loaded chitosan nanoparticles, H9c2 cells
were seeded on 6 well plates (0.15106 cells/well) and treated as follows: 1) control cells-no
treatment; 2) ISO treated-ISO (10 mM); 3) ISOþ25 nM siRNA-Npr3 (target 1); 4) ISOþ50 nM siRNA-
Npr3 (target 1); 5) ISOþ25 nM scrambled siRNA (target 1); 6) ISOþ50 nM scrambled siRNA (target 1);
7) ISOþ25 nM siRNA-Npr3 (target 2); 8) ISOþ50 nM siRNA-Npr3 (target 2); 9) ISOþ25 nM scrambled
siRNA (target 2); 10) ISOþ50 nM scrambled siRNA (target 2). At the end of 48 h of treatment, NPR-C
expression was analyzed by RT-PCR and Western blotting analysis. The RT-PCR and Western blotting
analysis showed a signiﬁcantly (3-fold) increased Npr3 gene expression on treatment with ISO. Upon
co-treatment with siRNA target 1 (25 nM) and target 2 (25 nM), the level of Npr3 gene expression was
found to be decreased by 1.5-fold, respectively (Fig. 3A–H).Fig. 2. Biocompatibility, hemocompatibility and targeting efﬁcacy of siRNA-Npr3 loaded chitosan nanoparticles, in vivo: A)
cytotoxicity of chitosan nanoparticles on H9c2 cells by MTT assay. Data are represented as mean7S.E.M. (n¼3), where, a –
untreated vs chitosan nanoparticles (Non-signiﬁcant), b – untreated vs siRNA-Npr3 nanoparticles (Non-signiﬁcant), c –
untreated vs scrambled siRNA nanoparticles (Non-signiﬁcant), B) Representative image of hemocompatibility of the chitosan
nanoparticles on erythrocytes where, (a) treatment with 1% triton X 100 (positive control), (b) treatment with chitosan
nanoparticles, (c) treatment with siRNA-Npr3 loaded chitosan nanoparticles and (d) treatment with scrambled siRNA nano-
particles. C) Representative immunoblot analysis of NPR-C protein expression on treatment with different dose of siRNA-Npr3,
where lane 1 – Control, 2 – ISO-treated for 7 days, 3 – ISOþsiRNA-Npr3 nanoparticles (2.5 mg/kg body weight), 4 – ISOþsiRNA-
Npr3 nanoparticles (5 mg/kg body weight). D) Densitometric analysis of NPR-C immunoblot. Data are represented as mean7S.
E.M. (n¼6 rats). *-Po0.01 – Control vs ISO-treated, #-Po0.05 – ISO-treated vs ISOþsiRNA-Npr3 (dose 1), -^Po0.01 – ISO-
treated Vs ISOþsiRNA-Npr3 (dose 2).
Fig. 3. Validation of siRNA-Npr3 loaded chitosan nanoparticles on H9c2 cells in vitro: A) and B) Representative RT-PCR and densi-
tometry of Npr3 gene expression, respectively. C) and D) Representative immunoblot and densitometry of NPR-C protein expression,
respectively, where L-100 bp DNA ladder, Lane 1 – control, 2 – ISO-treated, 3 – ISOþsiRNA target 1(25 nM), 4 – ISOþsiRNA target 1
(50 nM), 5 – ISOþscrambled siRNA target 1(25 nM), 6 – ISOþscrambled siRNA target 1(50 nM). Data are represented as mean7S.E.
M. (n¼3). *-Po0.01 – Control vs ISO-treated, #-Po0.05 – ISO-treated vs ISOþsiRNA target 1(25 nM), ##-Po0.01 – ISO-treated vs
ISOþsiRNA target 1(50 nM), -^Non-signiﬁcant – ISO-treated vs ISOþscrambled siRNA target 1(25 nM), -^Non-signiﬁcant – ISO-treated
vs ISOþscrambled siRNA target 1 (50 nM). E) and F) Representative RT-PCR and densitometry of Npr3 gene expression, respectively. G)
and H) Representative immunoblot and densitometry of NPR-C protein expression, respectively, where L-100 bp DNA ladder, Lane 1 –
control, 2 – ISO-treated, 3 – ISOþsiRNA target 2(25 nM), 4 – ISOþsiRNA target 2(50 nM), 5 – ISOþscrambled siRNA target 2(25 nM), 6
– ISOþscrambled siRNA target 2(50 nM). Data are represented as mean7S.E.M. (n¼3). *-Po0.01 – Control vs ISO-treated, #-Po0.05
– ISO-treated vs ISOþsiRNA target 2(25 nM), ##-Po0.01 – ISO-treated vs ISOþsiRNA target 2(50 nM), -^Non-signiﬁcant – ISO-treated
vs ISOþscrambled siRNA target 2(25 nM), -^Non-signiﬁcant – ISO-treated vs ISOþscrambled siRNA target 2 (50 nM).
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